Abstract 146P
Background
Esophageal cancer is an aggressive cancer with a poor prognosis. Prognostic factors are mainly based on cancer staging. HSPs are molecular chaperones that help protect against stress, often overexpressed in esophageal cancer. However, the prognostic significance and regulatory factors, such as HSF1 and CHIP, are poorly understood. To address the gap, a meta-analysis was conducted to investigate the relationship between HSP expression, prognosis-related factors, and clinicopathological features of esophageal cancer.
Methods
A systematic review was conducted by two reviewers on patients with esophageal cancer until Feb 15 2023. The study compared patients with positive HSP proteins to HSP-negative patients, analyzing grade of differentiation, lymph node metastasis, tumor depth, distant metastasis, and overall survival. HSP were stratified by HSP family, and summary risk difference (RD) were calculated using a random-effect model. Statistical heterogeneity was calculated using I2 statistic, and the risk and bias assessment, using the ROBINS-I tool. This study was conducted in accordance with PRISMA statement recommendations.
Results
Final selection comprised 27 studies, with a pooled sample size of 3465 patients. The mean age was 60.7 years old (46-69), with a male predominance. HSP40 and 60 were associated with a higher 3-year overall survival (HSP40 RD: 0.22; 95% CI: 0.09 to 0.35; HSP60 RD: 0.33; 95% CI: 0.17 to 0.50), while HSF1 was associated with a poor 3-year overall survival (RD: -0.22; 95% CI: -0.32 to -0.12). HSF1 was associated with a higher probability of lymph nodal metastasis (RD: -0.16; 95% CI: -0.29 to -0.04). HSP40 was associated with lower probability for lymph nodal dissemination (RD: 0.18; 95% CI: 0.03 to 0.33). HSP were not found to be related to lymph nodal metastasis, tumor depth or distant metastasis. Besides, HSPs were not related to grade of cellular differentiation.
Conclusions
Our systematic review and meta-analysis showed that the expressions of certain families of HSP, such as HSP40 and 60, HSF1 are associated with long-term survival and lymph nodal dissemination in patients with esophageal cancer. These findings support the role of HSP in susceptibility, progression and prognosis in esophageal cancer.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Universidade de São Paulo.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
41P - HLA genotypes modify the age-related penetrance of BRCA1 pathogenic variants in breast cancer patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - Investigating the influence of extrachromosomal DNA in the progression of non-small cell lung cancer through the TRACERx and PEACE studies
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
Presenter: Diego Gomez Puerto
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Exploring miR-205 and miR-296 as salivary biomarkers and potential therapeutic targets in oral cancer
Presenter: Thaís Moré Milan
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence
Presenter: Jinhwa Hong
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Differential expression of discriminative markers in matched invasion fronts and tumour buds in CRC
Presenter: Laura Grech
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Transcriptome profiling highlights distinct gene signatures in HER2 high (HER2 3+) and HER 2 low (Her2 1+/2+) breast cancers
Presenter: Tamanna Thakur
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - MiR-155 promotes breast cancer progression by upregulating cancer stemness
Presenter: Jeonghee Han
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - Clinical impact of actionable molecular variants disclosed in late-stage cancer patients by tumor whole-exome sequencing in a prospective single-institution study
Presenter: Christophe Mapendano
Session: Cocktail & Poster Display session
Resources:
Abstract